4593.T
HEALIOS K.K.
グロース · 医薬品 · 医薬品 · JP
JPY 293.00
−0.68%Aug 31, 2026, 11:00 UTC
Helios obtained a 'regenerative medicine product manufacturing and sales license' from the Hyogo Prefectural Governor.
Aug 19, 2026, 07:02 UTC
Healios announced that its low-immunogenicity iPS cell product 'Healios UDC' obtained a patent in China.
Aug 13, 2026, 04:46 UTC
Healios announced its consolidated results for the second quarter of fiscal year 2026 (January-June 2026), reporting revenue of 0.15 billion yen, down 74.9% year-on-year, an operating loss of 24.04 billion yen, a pretax loss of 22.78 billion yen, and a net loss attributable to owners of the parent of 22.86 billion yen.
Source: